Biohaven Pharmaceutical (BHVN) - Business Payback Period
Heavy reliance on external contractors for drug development and production determines the baseline P/E of Biohaven Ltd. on the GURU.Markets chart, where the metric remains at -4.30. Stable demand for neurodegenerative pathology therapies sustains customer loyalty. However, a lack of operating profit and costly research force Biohaven Ltd. to constantly deplete reserves and seek external financing.
Analytical breakdowns for Biohaven Pharmaceutical (BHVN)
- stock quotes and analyst forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
BHVN - Company Net Income|Expected Profit Biohaven Ltd.|BHVN - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Biohaven Ltd|BHVN - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Biohaven Ltd.|BHVN - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Biohaven|BHVN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biohavenpharma.com|BHVN - Earnings growth in current year|Expected earnings per share trend next year Biohaven Ltd.
Summary company analysis:BHVN (biohavenpharma.com)
Searching for sustainable assets requires analyzing the price-to-earnings ratio, which allows for the determination of the premium for future growth and the risks of overpayment. In the case of Biohaven Ltd. (BHVN), the company's P/E based on net income reflects speculative expectations regarding FDA approval, as the current stage of neurological drug trials makes this metric an indicator of market confidence in a future commercial launch.
Analysis of competing companies
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Business Payback Period Regencell Bioscience Ltd|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACADIA Corp (ACAD) - Market Cap to Earnings|Xenon Pharmaceuticals - P/E Multiple|Company Value to Net Income VKTX (vikingtherapeutics.com)|SUPN: P/E Multiple|Catalyst Pharma (CPRX) - P/E Multiple|Price to Earnings Ratio DNLI|Price to Earnings Ratio HRMY|P/E Multiple AMLX|TRVI - Market Cap to Earnings|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|AVXL: Price to Earnings Multiple|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (Prothena Corporation)|alector.com (ALEC) - Price to Earnings Ratio|ANNX (annexonbio.com) - Price to Earnings Ratio|Price to Earnings Ratio OMER|NGNE (Neurogene Inc) - Market Price to Net Income Ratio|P/E Multiple ACIU|Voyager Corp - Price to Earnings Multiple|Neumora Therapeutics - Price to Earnings Ratio|Business Payback Period scilexholding.com (SCLX)|Tevogen Bio - P/E Multiple|ACOG: Price to Earnings Ratio|CGTX: P/E Multiple|Inhibikase Pharma - Company Value to Net Income|Price to Earnings Ratio SAVA|Price to Earnings Ratio ASRT|Price to Earnings Ratio Coya Therapeutics, Inc. (COYA)|vistagen.com - Price to Earnings Multiple|Price to Earnings Ratio Ovid Therapeutics OVID|ABOS: Price to Earnings Multiple|CervoMed Inc. - P/E Multiple|Market Cap to Earnings Alterity Therapeutics|CLNN (clene.com) - Price to Earnings Ratio|PepGen (PEPG) - P/E Multiple|Price to Earnings Ratio Jupiter Neurosciences|RLMD: Company Value to Net Income|Price to Earnings Ratio Annovis Bio, Inc. (ANVS)|GRCE - Market Cap to Earnings|P/E Multiple AIFF (Firefly Neuroscience)|ANEW Medical - Price to Earnings Ratio|NeuroSense Therapeutics, Ltd. - P/E Multiple|Business Payback Period Reviva Pharmaceuticals, Inc. RVPH|metaviatx.com (MTVA) - Price to Earnings Ratio|Market Cap to Earnings neuraxis.com (NRXS)|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|PASG: Company Value to Net Income|P/E Multiple NEUP|P/E Multiple Minerva (NERV)|Athira Pharma, Inc. - Price to Earnings Ratio|addextherapeutics.com - Price to Earnings Ratio|Alzamend - P/E Multiple|Market Cap to Earnings Cyclerion Therapeutics|protagenic.com (PTIX) - Price to Earnings Ratio|Price to Earnings Multiple KTTA|Price to Earnings Ratio CRGT|ATXI: Company Value to Net Income|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|Price to Earnings Ratio CARA (Cara Therapeutics Inc.)|Chromocell Therapeutics Corporation - Price to Earnings Ratio|Market Price to Net Income Ratio ELYM (Eliem Therapeutics, Inc.)|Intra-Cellular - P/E Multiple|LBPH (longboardpharma.com) - Price to Earnings Multiple|MRNS (Marinus Pharmaceuticals, Inc.) - Price to Earnings Ratio|NKGN - Business Payback Period|NRBO (NeuroBo) - P/E Multiple|Price to Earnings Ratio SAGE|P/E Multiple SNPX|TRVN (trevena.com) - Company Value to Net Income|Vigil Neuroscience, Inc. - Price to Earnings Ratio|anewmeds.com - Price to Earnings Ratio|CERE - Price to Earnings Ratio
